RJA
CRNX icon

Raymond James & Associates’s Crinetics Pharmaceuticals CRNX Stock Holding History

Raymond James & Associates’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$376K Buy
7,358
+494
+7% +$25.5K ﹤0.01% 3271
2024
Q2 		$307K Buy
6,864
+236
+4% +$10.9K ﹤0.01% 3364
2024
Q1 		$310K Buy
+6,628
New +$259K ﹤0.01% 3359

Other funds holding CRNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Raymond James & Associates's CRNX Position: Q3 2024 in Review

Raymond James & Associates increased its Crinetics Pharmaceuticals (CRNX) stake by 7.2% in Q3 2024, buying an estimated $25.5K and bringing the position to 7,358 shares worth $376K. The position accounts for ﹤0.01% of the portfolio, ranked #3271.

Raymond James & Associates first reported a position in CRNX in Q1 2024 and has held it in 3 quarters since. 235 funds tracked by Wall St. Rank hold CRNX as of Q3 2024.

  • Raymond James & Associates held 7,358 shares of Crinetics Pharmaceuticals worth $376K as of Q3 2024.
  • Raymond James & Associates bought 494 Crinetics Pharmaceuticals shares in Q3 2024, an estimated $25.5K.
  • Crinetics Pharmaceuticals made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #3271 holding.
  • Raymond James & Associates first reported a position in Crinetics Pharmaceuticals in Q1 2024 and has held it in 3 quarters since.
  • 235 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.